Entrada Therapeutics (TRDA) Income from Continuing Operations (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Income from Continuing Operations of 39717000.0 for Q1 2026, down 128.93% year-over-year from 137288350.87 in Q1 2025, and down 1.39% quarter-over-quarter from 39172000.0 in Q4 2025.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 39717000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 128.93% year-over-year to 39717000.0; the TTM figure through Mar 2026 stood at 166148000.0 (down 771.6% YoY), while the FY2025 annual figure was 143726000.0, down 319.01% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 39717000.0, down from 39172000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 54989000.0 in Q2 2024, with the low at 44134000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 21671000.0 (2022), against an average of 12892411.76.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations soared 452.05% in 2024, then plunged 3563.48% in 2025.
- Entrada Therapeutics' Income from Continuing Operations stood at 24629000.0 in 2022, then surged by 61.42% to 9503000.0 in 2023, then surged by 111.9% to 1131000.0 in 2024, then slumped by 3563.48% to 39172000.0 in 2025, then declined by 1.39% to 39717000.0 in 2026.
- Business Quant data shows TRDA's Income from Continuing Operations at 39717000.0 in Q1 2026, 39172000.0 in Q4 2025, and 44134000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Entrada Therapeutics | 298.08 Mn | 298.08 Mn | - | -42.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.76 Mn |
| Mar 31, 2026 | -39.72 Mn |
| Dec 31, 2025 | -39.16 Mn |
| Sep 30, 2025 | -44.18 Mn |
| Jun 30, 2025 | -43.10 Mn |
| Mar 31, 2025 | -17.35 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | -13.99 Mn |
| Jun 30, 2024 | 54.99 Mn |
| Mar 31, 2024 | 23.50 Mn |
| Dec 31, 2023 | -9.50 Mn |
| Sep 30, 2023 | 35.46 Mn |
| Jun 30, 2023 | -25.93 Mn |
| Mar 31, 2023 | -6.72 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -25.14 Mn |
| Jun 30, 2022 | -23.18 Mn |
| Mar 31, 2022 | -21.67 Mn |
| Dec 31, 2021 | -18.45 Mn |
| Sep 30, 2021 | -14.43 Mn |